| 6608 |
Centers for Disease Control and Prevention |
Html |
en |
Preventing chronic disease in women of reproductive age: opportunities for health promotion and preventive services. |
Improving the health of women of reproductive age extends beyond focusing on pregnancy and birth outcomes. Approaching women’s health from a life course perspective offers an opportunity to reduce overall and pregnancy-related illnesses and deaths and to eliminate disparities through enhanced health promotion and disease prevention. |
| preconception health awareness | 0.418775 |
| Health Resource Services | 0.416545 |
| public health interventions | 0.401773 |
| u.s. medical eligibility | 0.503802 |
| Child Health Bureau | 0.406946 |
| chronic heart disease | 0.545078 |
| chronic disease risk | 0.459173 |
| women’s health | 0.455709 |
| certain chronic diseases | 0.399288 |
| Disease Control | 0.573611 |
| chronic disease conditions | 0.459235 |
| National Center | 0.450368 |
| risk factors | 0.512431 |
| World Health Organization | 0.402253 |
| chronic medical conditions | 0.440363 |
| interconception health status | 0.388488 |
| Affordable Care Act | 0.428067 |
| health status | 0.390648 |
| Health Statistics | 0.379084 |
| chronic disease | 0.92193 |
| wellness health screening | 0.405154 |
| chronic disease prevention | 0.696979 |
| women | 0.496631 |
| sexually active women | 0.370916 |
| adverse pregnancy outcomes | 0.363831 |
|
| United States | 0.362636 |
| Child Health Epidemiology | 0.409062 |
| state health policies | 0.404081 |
| health promotion | 0.550523 |
| project targeted women | 0.35938 |
| reproductive-aged women | 0.361072 |
| Pregnancy Risk Assessment | 0.447248 |
| public health approach | 0.394759 |
| state health department | 0.415169 |
| public health | 0.473586 |
| chronic disease–related risk | 0.433735 |
| chronic diseases | 0.463052 |
| interconception health services | 0.407041 |
| reproductive age | 0.792688 |
| postpartum health visits | 0.395105 |
| health | 0.703296 |
| chronic disease programs | 0.450704 |
| chronic conditions | 0.358994 |
| health care visits | 0.405041 |
| medical eligibility criteria | 0.500493 |
| Public Health Service | 0.388153 |
| chronic disease prevalence | 0.466741 |
| Risk Assessment Monitoring | 0.435115 |
| various chronic disease | 0.453192 |
|
CLICK HERE |
| 6715 |
Centers for Disease Control and Prevention |
Html |
en |
Bat Influenza (Flu) |
Bat Influenza (Flu) - CDC |
| South America | 0.340263 |
| form bat flu | 0.358587 |
| CDC | 0.27535 |
| surface protein-coding gene | 0.23206 |
| Global Disease Detection | 0.230817 |
| Central | 0.229413 |
| high-throughput sequencing instruments | 0.230934 |
| new flu viruses | 0.40172 |
| CDC Rabies program | 0.243425 |
| Regional Center | 0.230747 |
| GDD Guatemala Regional | 0.232832 |
| single host cell | 0.234813 |
| pathogenic viruses | 0.284401 |
| new bat flu | 0.388209 |
| bat populations | 0.251686 |
| laboratory research | 0.240233 |
| different bat flu | 0.355324 |
| CDC’s Division | 0.23013 |
| human flu viruses | 0.509683 |
| CDC’s laboratories | 0.228947 |
| healthy bats | 0.231905 |
| human respiratory tract | 0.232166 |
| new animal species | 0.235577 |
| little yellow-shouldered bats | 0.285597 |
| bat flu viruses | 0.848328 |
|
| significant changes | 0.239997 |
| flu virus biology | 0.312721 |
| dangerous viruses | 0.291165 |
| continental United States | 0.237564 |
| CDC’s Pathogen | 0.230309 |
| bat flu virus | 0.425097 |
| bats | 0.295197 |
| flu researchers | 0.303897 |
| internal genes | 0.25942 |
| genetic information | 0.23186 |
| Preliminary laboratory research | 0.234843 |
| CDC scientists | 0.264762 |
| considerable genetic diversity | 0.231735 |
| monitor flu viruses | 0.392639 |
| flu viruses | 0.958453 |
| HA surface proteins | 0.237191 |
| Universidad del Valle | 0.230245 |
| Flu scientists | 0.30037 |
| Pathogen Discovery Program | 0.297388 |
| NA surface proteins | 0.262456 |
| surface proteins | 0.281751 |
| ancient bat flu | 0.348958 |
| Initial viral screening | 0.229626 |
| bat influenza viruses | 0.339421 |
|
CLICK HERE |
| 9581 |
Centers for Disease Control and Prevention |
Html |
en |
CDC Newsroom Image Library Buildings and Facilities | CDC Media Relations |
Free public health images, medical images, high-resolution, public domain images. |
| PHIL ID number | 0.258483 |
| James Gathany | 0.38262 |
| organization′s Roybal Campus | 0.366596 |
| content provider | 0.284851 |
| Tom Harkin Global | 0.24594 |
|
| Disease Control | 0.381703 |
| CDC′s Roybal campus | 0.942536 |
| Emergency Operations Center | 0.671335 |
| Photo Credit | 0.38317 |
| Arlen Specter Headquarters | 0.809351 |
|
CLICK HERE |
| 9990 |
Centers for Disease Control and Prevention |
Html |
en |
Daniel Payne | Conversations with the Director | CDC Director | CDC |
The CDC Director’s webpage offers information on Dr. Thomas Frieden, who became the agency’s 16th director in June 2009. The pages features information on Dr. Frieden’s Weekly Focus, the Latest from Dr. Frieden (his RSS feed), and links to his bio, statements, videos, press releases, media appearances, photos, presentations, and speeches. |
| MPEG | 0.378858 |
| search | 0.263099 |
| PDF | 0.261307 |
| PPT | 0.446092 |
|
| DOC | 0.368812 |
| information | 0.262482 |
| different file formats | 0.938484 |
| page | 0.276773 |
|
CLICK HERE |
| 10016 |
Centers for Disease Control and Prevention |
Html |
en |
Guide to Writing for Social Media | Social Media | CDC |
Basic information from CDC about breast cancer. |
| CDC | 0.448034 |
| social media messages | 0.419143 |
| family physicians | 0.370493 |
| social media communication | 0.399877 |
| Audience Insights—Communicating | 0.382458 |
| social media audiences | 0.403942 |
| social media efforts | 0.398027 |
| social media content | 0.490533 |
| different social media | 0.397144 |
| social media tools | 0.448401 |
| social media channels | 0.487931 |
| effective social media | 0.402917 |
| Facebook | 0.403155 |
| social media writers | 0.400796 |
| Social Media Guidelines | 0.444297 |
| CDC share health | 0.374348 |
| Social Media Toolkit | 0.398926 |
| social media information | 0.410441 |
| CDC health communication | 0.387822 |
| text messages | 0.5001 |
| plain language | 0.458863 |
| health literacy | 0.401381 |
| social marketing concepts | 0.374632 |
| social media communications | 0.39506 |
| United States | 0.381845 |
|
| commonly recognized abbreviations | 0.37452 |
| Twitter | 0.393407 |
| Web content | 0.420416 |
| cell phone | 0.3882 |
| short message service | 0.384241 |
| 140 characters | 0.375579 |
| social marketing | 0.432674 |
| social media activities | 0.401395 |
| social media message | 0.41907 |
| Social Marketing Practice | 0.370323 |
| Electronic Media Branch | 0.370049 |
| Relevant social media | 0.395672 |
| Interesting social media | 0.389111 |
| social media | 0.952927 |
| social networking sites | 0.397329 |
| Facebook post | 0.375911 |
| cell phones | 0.372524 |
| health | 0.424909 |
| CDC’s Audience | 0.398843 |
| Social Media Content–Types | 0.380529 |
| social media strategy | 0.419974 |
| Web page | 0.397893 |
| best practices | 0.379598 |
| social media channel | 0.399896 |
|
CLICK HERE |
| 10948 |
Centers for Disease Control and Prevention |
Html |
en |
Prostate Cancer Screening Tests |
Two tests are commonly used to screen for prostate cancer: a digital rectal exam and a prostate specific antigen (PSA) test. |
| nurse inserts | 0.33411 |
| rule | 0.221582 |
| prostate infection | 0.52106 |
| PSA level | 0.645157 |
| Digital rectal exam | 0.448317 |
| men | 0.221792 |
| PSA levels | 0.642207 |
| PSA test results | 0.62408 |
| PSA | 0.803107 |
| finger | 0.226242 |
| best person | 0.314889 |
| abnormalities | 0.231299 |
| enlarged prostate | 0.53696 |
| substance | 0.224368 |
| prostate glands | 0.535193 |
| blood | 0.268394 |
| prostate problem | 0.530339 |
|
| Cancer screening | 0.333161 |
| factors | 0.244295 |
| lumps | 0.23475 |
| doctor | 0.2439 |
| symptoms | 0.22486 |
| prostate cancer | 0.615552 |
| prostate cancer— | 0.565113 |
| Certain medical procedures | 0.41974 |
| tests | 0.223438 |
| size | 0.222707 |
| Certain medications | 0.32655 |
| DRE | 0.233645 |
| biopsy | 0.228873 |
| prostate | 0.951934 |
| rectum | 0.237536 |
| prostate cancers | 0.604513 |
|
CLICK HERE |
| 12956 |
Centers for Disease Control and Prevention |
Html |
en |
Stressful Life Events Experienced by Women in the YearBefore Their Infants' Births - United States, 2000-2010 |
Elizabeth R. Burns, MPH1, Sherry L. Farr, PhD2, Penelope P. |
| preterm birth | 0.484636 |
| demographic characteristics | 0.615072 |
| data | 0.517394 |
| birth certificate data | 0.491513 |
| recent population-based study | 0.486662 |
| lowest prevalence | 0.486543 |
| highest prevalence | 0.491384 |
| financial stressors | 0.494962 |
| stressors | 0.497285 |
| maternal demographics | 0.631495 |
| New York City | 0.66007 |
| Penelope P. Howards | 0.480059 |
| pregnant women | 0.549397 |
| Health Promotion | 0.48815 |
| stressful life event | 0.479933 |
| traumatic stressors | 0.495726 |
| maternal demographic characteristics | 0.580341 |
| York City health | 0.480318 |
| National Center | 0.492313 |
| social support | 0.489655 |
| mean number | 0.656348 |
| unmarried women | 0.490334 |
| women | 0.74212 |
| SLEs | 0.904419 |
| Reproductive Health | 0.485877 |
|
| traumatic SLEs | 0.519002 |
| percentage points | 0.545486 |
| prevalence | 0.656112 |
| West Virginia | 0.548506 |
| Pregnancy Risk Assessment | 0.483327 |
| live birth | 0.537465 |
| emotional stressors | 0.491406 |
| prevalence estimate | 0.481441 |
| PRAMS data | 0.489687 |
| highest point prevalence | 0.512568 |
| public health | 0.512227 |
| Sherry L. Farr | 0.546491 |
| lowest point prevalence | 0.516293 |
| SLE constructs | 0.610814 |
| lowest mean number | 0.521402 |
| PRAMS | 0.556363 |
| response rates | 0.550487 |
| individual SLE constructs | 0.49743 |
| Chronic Disease Prevention | 0.564637 |
| CDC PRAMS Team | 0.49743 |
| frequently reported type | 0.513641 |
| financial SLEs | 0.517042 |
| low birth weight | 0.547817 |
| maternal SLEs | 0.492602 |
|
CLICK HERE |
| 13924 |
Centers for Disease Control and Prevention |
Html |
en |
Notes from the Field: Carbapenem-resistantEnterobacteriaceae Producing OXA-48-like Carbapenemases - UnitedStates, 2010-2015 |
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC). Often called 'the Voice of CDC,' the MMWR series is the agency's primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations. MMWR readership predominately consists of physicians, nurses, public health practitioners, epidemiologists and other scientists, researchers, educators, and laboratorians. |
| U.S. reports | 0.22594 |
| rapid global dissemination | 0.328095 |
| carbapenemase-producing CRE | 0.619213 |
| additional published reports | 0.329127 |
| OXA-48 carbapenemase | 0.236227 |
| CDC Health Advisory | 0.335635 |
| U.S. clinical laboratories | 0.301224 |
| Zoonotic Infectious Diseases | 0.305979 |
| Maroya Walters | 0.237775 |
| different susceptibility profiles | 0.307609 |
| K. pneumoniae | 0.37804 |
| carbapenem antibiotics | 0.232509 |
| OXA-48-like carbapenemase genes | 0.347322 |
| patients | 0.547463 |
| OXA-48-like carbapenemases | 0.777871 |
| Brandi Limbago | 0.241756 |
| carbapenemase enzymes | 0.236561 |
| Kamile Rasheed | 0.251654 |
| Klebsiella pneumoniae carbapenemase | 0.403571 |
| Meghan Lyman | 0.250921 |
| CRE | 0.806063 |
| health care settings | 0.308734 |
| high transfer efficiency | 0.302421 |
| 1Epidemic Intelligence Service | 0.30877 |
|
| Klebsiella ozaenae isolate | 0.354316 |
| health care–associated infections | 0.342189 |
| United States | 0.913286 |
| CDC CRE surveillance | 0.596093 |
| Meghan M. Lyman | 0.316523 |
| non-K. pneumoniae carbapenemases | 0.351619 |
| Healthcare Quality Promotion | 0.308541 |
| New Delhi metallo-β-lactamase | 0.549854 |
| plasmid-mediated resistance | 0.244786 |
| OXA-48-producing CRE | 0.476667 |
| public health concern | 0.340617 |
| frequently reported destination | 0.321945 |
| different clusters | 0.225961 |
| Alexander Kallen | 0.242078 |
| high mortality rates | 0.336818 |
| OXA-48-like genes | 0.232859 |
| OXA-48-like variants | 0.247702 |
| CRE resistance mechanisms | 0.585753 |
| enhanced environmental cleaning | 0.329196 |
| CRE screening | 0.481109 |
| Newly described resistance | 0.344355 |
| David Lonsway | 0.239262 |
| U.S. K. pneumoniae | 0.370653 |
| isolates | 0.313706 |
|
CLICK HERE |
| 14385 |
Centers for Disease Control and Prevention |
Html |
en |
Food and Drug Administration Approval for Use of Hiberix asa 3-Dose Primary Haemophilus influenzae Type b Hib VaccinationSeries | MMWR |
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC). |
| vaccine shortage | 0.676719 |
| Haemophilus influenzae type | 0.730224 |
| apparent seizure disorder | 0.659967 |
| Rotavirus Vaccine | 0.658312 |
| Elizabeth C. Briere | 0.65032 |
| Human Services | 0.647171 |
| PRP-T vaccines | 0.622454 |
| 13-valent Conjugate Vaccine | 0.779073 |
| Hib vaccination schedules | 0.78261 |
| U.S. Department | 0.649015 |
| vaccine administration | 0.64413 |
| Injection site pain | 0.65111 |
| electronic PDF version | 0.657087 |
| GlaxoSmithKline Biologicals | 0.607838 |
| currently licensed monovalent | 0.690946 |
| open label study | 0.669545 |
| Noninferiority criteria | 0.655478 |
| single booster dose | 0.786963 |
| infants | 0.753771 |
| Tetanus Toxoid Conjugate | 0.939964 |
| immunogenicity assessment | 0.608367 |
| adverse event | 0.610313 |
| Conjugate Vaccine | 0.884632 |
| vaccination series.* Hiberix | 0.795626 |
|
| vaccine option | 0.667854 |
| tetanus toxoids | 0.633935 |
| booster dose | 0.798203 |
| Research Triangle Park | 0.689166 |
| 3-dose primary series | 0.709352 |
| insert (http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM179530.pdf). | 0.654407 |
| ActHIB | 0.619647 |
| timely booster vaccination | 0.736794 |
| Haemophilus b Conjugate | 0.768661 |
| primary vaccination series | 0.915564 |
| United States | 0.698118 |
| original MMWR paper | 0.662044 |
| healthy infants | 0.664591 |
| DTaP/IPV/Hib combination vaccine | 0.719635 |
| Hiberix group | 0.619103 |
| μg tetanus | 0.648769 |
| adverse events | 0.780875 |
| anti-PRP response | 0.654469 |
| invasive Hib disease | 0.712539 |
| combination Hib vaccines | 0.761137 |
| capsular polyribosyl ribitolphosphate | 0.690053 |
| infant primary vaccination | 0.770037 |
| μg/ml | 0.617453 |
| routine childhood vaccines | 0.690407 |
|
CLICK HERE |
| 16008 |
Centers for Disease Control and Prevention |
Html |
null |
Safety of Influenza Vaccines |
Safety of Influenza Vaccines - CDC |
|
|
CLICK HERE |